Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one
Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one
复制标题
DOI：
10.1016/s0264-410x(97)00217-x
复制
发表时间：
1997-04-01
期刊：
影响因子：
5.5
通讯作者：
Coleclough, C
中科院分区：
文献类型：
--
作者：
Hurwitz, JL;Soike, KF;Coleclough, C
人类副流感病毒I型（hPIV-1）感染是幼儿“集体”和住院的常见原因。在这里，我们探讨了使用异向性仙台病毒[一种小鼠副流感病毒（PIV）]作为hPIV-1疫苗的可能性。通过鼻内途径对6只非洲绿猴（Cercopithecus aethiops）施用仙台病毒。在血清和鼻腔中都产生了持久的病毒特异性抗体反应。仙台病毒在灵长类动物中未引起明显的临床症状，但接种后数天在鼻腔中检测到活病毒。在第一次引物126天后，第二次接种仙台病毒，未检测到病毒。在第154天用hPIV-1感染动物。所有6只接种疫苗的动物都完全免受感染，而6只对照动物中有6只感染了hPIV-1。仙台病毒免疫诱导的抗体应答比hPIV-1免疫诱导的抗体应答要大。这些结果表明，未经处理的仙台病毒在灵长类动物模型中是抗hPIV-1的有效疫苗，并可能构成用于人类的实用疫苗。1997爱思唯尔科学有限公司
Human paraininfluenza virus-type I (hPIV-1) infections are a common cause of ''croup'' and hospitalizations among young children. Here we address the possibility, of using the xenotropic Sendai virus [a mouse parainfluenza virus (PIV)] as a vaccine for hPIV-1. Sendai virus was administered to six African green monkeys (Cercopithecus aethiops) by, the intranasal (i.n.) route. A long lasting virus-specific antibody, response was elicited, both in the serum and nasal cavity. Sendai virus caused no apparent clinical symptoms in the primates, but live virus was detected in the nasal cavity for several days after inoculation. No virus was detected after a second dose of Sendai virus was administered on day 126 after the initial priming. Animals were challenged with hPIV-1 i.n. on day 154. All six vaccinated animals were fully protected from infection while six of six control animals were infected with hPIV-1. The antibody responses induced by Sendai virus immunizations proved to be greater than those induced by hPIV-1. These results demonstrate that unmanipulated Sendai virus is art effective vaccine against hPIV-1 in a primate model and may constitute a practical vaccine for human use. (C) 1997 Elsevier Science Ltd.